ramipril krka
krka pharma dublin limited - ramipril - tablets - 1.25 milligram
ramipril krka
krka pharma dublin limited - ramipril - tablets - 2.5 milligram
ramipril krka
krka pharma dublin limited - ramipril - tablets - 5 milligram
ramipril krka
krka pharma dublin limited - ramipril - tablets - 10 milligram
levocetirizine krka 5mg film-coated tablets
krka pharma dublin limited - levocetirizine dihydrochloride - film coated tablet - 5 milligram
perindopril krka
krka pharma dublin limited - perindopril tert-butylamine - tablets - 2 milligram
perindopril krka
krka pharma dublin limited - perindopril tert-butylamine - tablets - 4 milligram
perindopril krka
krka pharma dublin limited - perindopril tert-butylamine - tablets - 8 milligram
abiraterone krka
krka, d.d., novo mesto - abiraterone acetate - prostatic neoplasms - endocrine therapy - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5.1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
atazanavir krka
krka, d.d., novo mesto - atazanavir (as sulfate) - hiv infections - antivirals for systemic use - atazanavir krka capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 pi mutations).the choice of atazanavir krka in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.